MAM
Reebok launches Rockport Spring/Summer collection
BANGALORE: Rockport, brought to India by Reebok India Company, has announced the launch of its Spring/Summer ’05 collection. Priced at Rs 5,990 and RS 4,490, respectively, these shoes come with DMX technology applied to a Rockport comfort foot bed.
DMX is a dynamic air transfer system, which creates cushions of moving air for an unprecedented level of comfort. Available in white/black and white/tan combinations at Rockport exclusive and select Reebok stores across the country, informs a company release.
Rockport has also announced the launch of Sebring I.O shoes from the I.Travel range as part of their Spring/Summer ’05 collection. Targeting comfort for customers from the street to the boardroom, Sebring I.O shoes is priced at RS 4,490. Available in black and tan, these shoes come with stroebel construction for forefoot flexibility to aid the walking motion.
The Footbed has EVA filler for lightweight cushioning for reducing foot and leg fatigue. Rubber midsole provides a durable grip on a variety of surfaces. These shoes will be available at Rockport exclusive and select Reebok stores across the country, the release adds.
MAM
Cipla appoints Achin Gupta as MD and global CEO
Veteran pharma leader with 20-plus years takes charge from 1 April 2026, succeeding current MD.
MUMBAI: Cipla’s next chapter just got a seasoned prescription because when it comes to leading a pharma giant, Achin Gupta knows exactly which dose delivers results. The Mumbai-based drugmaker announced on 23 February 2026 that Achin Gupta, currently global chief operating officer, will step up as managing director and global chief executive officer from 1 April 2026. He succeeds the outgoing leadership team and will steer Cipla’s worldwide operations, market expansion, operational efficiency, and innovation pipeline across its broad portfolio of generics, specialty drugs, and consumer healthcare treatments.
Gupta brings more than 20 years of pharmaceutical industry experience to the corner office. Before rejoining Cipla, he spent over eight years at Glenmark Pharmaceuticals in senior roles, having also worked there earlier between 2004 and 2012. His career path also includes key stints at Abbott Laboratories and management consulting firm A.T. Kearney, giving him a well-rounded view of global pharma strategy, operations, and growth.
In his current COO role, Gupta has already been deeply involved in streamlining Cipla’s supply chain, boosting manufacturing agility, and driving digital transformation moves that positioned the company strongly amid post-pandemic supply challenges and rising competition. As MD and Global CEO, he’ll now have full accountability for executing Cipla’s long-term vision, from deepening presence in key markets like the US, Europe, and emerging regions to accelerating R&D in complex generics and biosimilars.
The appointment comes at a pivotal time for Cipla, as the industry navigates pricing pressures, regulatory shifts, and the push for affordable innovation in chronic therapies. Gupta’s track record of scaling operations and delivering consistent performance makes him a logical internal choice to keep the momentum going.
For a company that’s long been a household name in affordable medicines, this leadership handoff is less about a big shake-up and more about steady continuity with fresh energy ensuring the next dose of growth is as effective as the last.
